Stock Markets June 17, 2026 09:19 AM

Ocular Therapeutix Revises AXPAXLI Submission Plan; Stock Edges Lower After Investor Day

Company to target a Q4 2026 NDA filing based on SOL-1 Week 52 and interim SOL-R safety data; SOL-R topline efficacy deferred to 2028

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
OCUL

Ocular Therapeutix said it will pursue a New Drug Application for AXPAXLI in wet age-related macular degeneration in the fourth quarter of 2026, relying on SOL-1 Week 52 efficacy and safety results plus an interim SOL-R safety analysis to meet FDA alignment. The shift removes SOL-R efficacy from the submission package, pushes SOL-R topline efficacy readout to the first quarter of 2028, and prompted a modest 1% drop in the company’s shares following its Investor Day.

Ocular Therapeutix Revises AXPAXLI Submission Plan; Stock Edges Lower After Investor Day
OCUL
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Ocular Therapeutix plans to submit an NDA for AXPAXLI in wet AMD in Q4 2026 using SOL-1 Week 52 efficacy and safety data plus interim SOL-R safety data.
  • SOL-R efficacy data will not be part of the NDA; SOL-R topline efficacy results are now expected in Q1 2028, and the trial will remain masked through Week 96.
  • The company will pursue the NDA under the 505(b)(2) pathway and has streamlined its diabetic retinopathy program to prioritize HELIOS-3 as a potential single registrational trial for annual dosing.

Shares of Ocular Therapeutix (NASDAQ:OCUL) fell about 1% on Wednesday after the company used its Investor Day to lay out a revised regulatory and trial timeline for its lead candidate, AXPAXLI, in wet age-related macular degeneration.

The Bedford, Massachusetts-based biopharmaceutical firm said it reached agreement with the U.S. Food and Drug Administration at a Type C meeting in May 2026 on the data package the agency will accept for a New Drug Application. Specifically, Ocular said the planned NDA will be based on SOL-1 Week 52 efficacy and safety results together with interim safety data from its SOL-R study.

As part of that plan, the company intends to perform an interim safety analysis of SOL-R in the fourth quarter of 2026 to ensure the combined safety database from SOL-1 and SOL-R exceeds 300 patients, in keeping with FDA expectations. Ocular emphasized that SOL-R efficacy outcomes will not be included in the AXPAXLI NDA submission.

The company will still collect SOL-R efficacy information, but it is now positioning superiority of AXPAXLI against aflibercept (8 mg) administered every six months at Week 96 as a key secondary endpoint of the SOL-R trial. SOL-R will remain masked through Week 96, and topline efficacy results from that trial are now slated for the first quarter of 2028, a later timing than previously communicated.

Ocular indicated it plans to file the NDA under the 505(b)(2) regulatory pathway, which the company said could shorten the review period by up to 60 days. Separately, the company is narrowing its diabetic retinopathy program to prioritize HELIOS-3 as a potential single registrational trial to evaluate AXPAXLI dosed every 12 months.

Background on the clinical program included a reminder that the SOL-1 trial completed randomization of 344 treatment-naive subjects with wet AMD in December 2024. In February 2026, Ocular reported that 74.1% of subjects in the AXPAXLI arm maintained vision at Week 36 compared with the aflibercept arm, meeting the trial’s superiority primary endpoint with a p-value of 0.0006.

The aggregate of these decisions - basing the NDA on SOL-1 Week 52 plus interim SOL-R safety, removing SOL-R efficacy from the submission, and extending SOL-R topline timing - informed investors and coincided with a modest share price decline following the company’s Investor Day.


Regulatory and trial timeline at a glance

  • May 2026 Type C meeting with FDA - alignment to base NDA on SOL-1 Week 52 plus interim SOL-R safety data.
  • Q4 2026 - planned interim SOL-R safety analysis to reach more than 300 patients of combined safety data.
  • Q4 2026 - target window for submitting the AXPAXLI NDA under the 505(b)(2) pathway.
  • Week 96 of SOL-R - superiority versus aflibercept (8 mg) every six months to be assessed as a key secondary endpoint; SOL-R remains masked through Week 96.
  • Q1 2028 - expected topline SOL-R efficacy results.

These updates reflect a focused regulatory filing strategy while deferring a separate SOL-R efficacy readout to support longer-term comparative assessment.

Risks

  • Topline SOL-R efficacy results have been deferred to Q1 2028, creating timing uncertainty for comparative efficacy readouts that could affect investor expectations - this impacts biotech and healthcare market timing.
  • The NDA will rely on an interim SOL-R safety analysis to reach a combined safety database of more than 300 patients; if the interim analysis does not meet expectations, regulatory plans could be affected - this is a regulatory risk for the biopharma sector.
  • Removal of SOL-R efficacy data from the submission package means longer wait for head-to-head superiority evidence versus aflibercept, which could influence payer and provider uptake discussions - this affects commercial positioning in ophthalmology therapies.

More from Stock Markets

Options Pricing Signals an 11% Move for Micron Ahead of June 24 Results Jun 17, 2026 Casablanca Close: Moroccan All Shares Flat as Major Names End Unchanged Jun 17, 2026 Johnson & Johnson Will Pass on Obesity Drugs, Redirecting R&D Toward Cancer and Neuroscience Jun 17, 2026 Critical Metals Share Price Gains After 10,000-Meter Drill Program Begins at Tanbreez Jun 17, 2026 Tel Aviv Gauge Falls as Technology, Communication and Real Estate Stocks Weigh on Market Jun 17, 2026